

JENRIN DISCOVERY, INC.

Jenrin Discovery is developing a novel approach to the treatment of obesity. Obesity, with its accompanying risk of serious health problems, is at epidemic proportions, and its incidence is rising. Until now, anti-obesity therapies have worked either by suppressing food intake, increasing metabolic activity or blocking food absorption. Yet these drugs produce only modest weight loss that is generally not sustained, and several have encountered safety issues. There is an urgent need for more effective, safe therapies to help individuals manage their weight, and successful products are expected to have multi-billion dollar worldwide sales potential.

Jenrin Discovery has a wholly different approach—it is developing drugs that act directly to eliminate adipose (fat) tissue through a novel mechanism discovered by Jenrin's founder and called the JDO binding site. In a 14-week proof-of-concept animal study, Jenrin's pilot compound showed that agents that inhibit the JDO binding site result in a 14% decrease in body weight, a significantly greater weight loss than is achieved with current FDA-approved weight loss drugs. Perhaps most significantly, the weight loss was due to an impressive 30% reduction in body fat, and was not accompanied by reduced food intake. Since this binding site also exists in the central nervous system (CNS), Jenrin is currently developing drug candidates that act only on the peripheral binding sites in adipose tissue, eliminating the possibility of CNS effects.

BioAdvance Greenhouse funding will be used to optimize drug candidates and select the best one to take forward into human clinical testing. Jenrin Discovery expects to identify and then collaborate with major pharmaceutical partners to develop safe therapeutic agents that are effective in producing meaningful and sustained weight loss, with the potential to generate large sales while having a major medical and societal impact.

Management

John McElroy, Ph.D., Founder, President and CSO, has 15 years of experience in the pharmaceutical industry, as well as extensive experience in anti-obesity research, beginning during his doctoral and post-doctoral studies investigating central and peripheral mechanisms of obesity. Before founding Jenrin Discovery, Dr. McElroy served as Director, Neuroscience Biology, Bristol-Myers Squibb. Dr. McElroy is the inventor of several patents and the author of over 40 scientific publications. He received his Ph.D. from the University of Massachusetts.

Robert Chorvat, Ph.D., Director of Medicinal Chemistry (Consultant), has over 25 years of medicinal chemistry experience with a proven drug discovery track record. Currently Dr. Chorvat is director of medicinal chemistry business development at TimTec Corporation, which evaluates, organizes and markets compound libraries. He is an inventor on more than 40 patents and an author of more than 40 publications. He received his Ph.D. from the Illinois Institute of Technology.

For more information contact Dr. John McElroy, Jenrin Discovery, Inc. at j.mcelroy@jenrindiscovery.com.